Stealth BioTherapeutics (Stealth BioTherapeutics) LT-Debt-to-Total-Asset : 0.37 (As of Mar. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Stealth BioTherapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Stealth BioTherapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2022 was 0.37.

Stealth BioTherapeutics's long-term debt to total assets ratio increased from Mar. 2021 (0.00) to Mar. 2022 (0.37). It may suggest that Stealth BioTherapeutics is progressively becoming more dependent on debt to grow their business.

Stealth BioTherapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Stealth BioTherapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stealth BioTherapeutics LT-Debt-to-Total-Asset Chart

Stealth BioTherapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

8.66

7.32

0.03

0.27

Stealth BioTherapeutics Quarterly Data
	Dec16	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	0.31	0.27	0.37

Stealth BioTherapeutics LT-Debt-to-Total-Asset Calculation

Stealth BioTherapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

LT Debt to Total Assets (A: Dec. 2021 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2021 )	/	Total Assets (A: Dec. 2021 )
	=	13.656	/	50.226
	=

Stealth BioTherapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2022 is calculated as

LT Debt to Total Assets (Q: Mar. 2022 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2022 )	/	Total Assets (Q: Mar. 2022 )
	=	13.782	/	36.915
	=

Stealth BioTherapeutics (NAS:MITO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Stealth BioTherapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Stealth BioTherapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Stealth BioTherapeutics (Stealth BioTherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stealth BioTherapeutics Corp (NAS:MITO) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

c/o Intertrust Corporate Services (Cayman) Limited, One Nexus way, Camana Bay, Grand Cayman, CYM, KY1-9005

Website

https://www.stealthbt.com

Stealth BioTherapeutics Corp is a clinical-stage biotechnology company. It is focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction.